Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 1997

View Archived Issues

New alpha1-adrenoceptor antagonists from Roche

New antiasthma agents reported by Sandoz

Antifungal echinocandin derivatives reported by Lilly

Novel cytotoxic protein derived from bacterial source

ACCORD study results reported in Circulation

Roche presents new antifungal agents

MMP inhibitors disclosed by Fuji Yakuhin

Cerebrus discovers role of gene in obesity

Glaxo Wellcome selects anticonvulsant compound for further study

Thrombin inhibitors submitted to SAR studies at DuPont Merck

Merck & Co. investigates thrombin inhibitors

Additional beneficial lipid-modifying effects of FCP-3P1 reported

Merck Frosst discovers orally active COX-2 inhibitors

ICOS MAb to enter clinic

Positive phase II results reported for platelet substitute

SIBIA receives patent coverage for antiparkinson compounds

Brain cancer gene identified

Boston Life Sciences demonstrates efficacy of antiangiogenic factor

GEM-132 enters clinic in U.S.

Oncor technology covered by U.S. patent

New H. pylori test enters clinic

GelTex reports CholestaGel phase II data

Company Profile: Molecular Design International

Fujisawa investigates tachykinin antagonists

Muse licensed to Janssen for certain markets

Abbott seeks expanded labeling for Norvir

Phase I trials begin for Fabry's disease

ERT and the renin-angiotensin system in postmenopausal women

Royce Laboratories receives FDA approval for alprazolam

FDA approves Royce's generic narcotic pain reliever

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...